[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mucormycosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mucormycosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,79,101,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641702","clinical-evaluation-of-patient-specific-3d-printed-titanium-implants-for-facial-reconstruction-100641702",false,"NCT07654647","Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.","Evaluation of the Effectiveness of Patient-Specific 3D-Printed Titanium Facial Implants in the Reconstruction and Aesthetic Correction of Facial Defects: A Clinical Study","3DFACE","Inclusion Criteria:\n\n* Age 18 years or older.\n* Presence of facial bone defects resulting from cystic or tumoral osteolytic lesions.\n* Acquired or congenital facial deformities associated with bony defects or facial asymmetry.\n* Patients requiring patient-specific 3D-printed titanium implants for maxillofacial reconstruction.\n* Aesthetic indications requiring custom facial implant design, including microgenia (chin retrusion).\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Active pathological lesions at the time of enrollment.\n* Age below 18 years.\n* History of radiotherapy within 12 months prior to enrollment.\n* Chronic untreated vitamin D deficiency.\n* Uncontrolled diabetes mellitus.\n* Inability or unwillingness to comply with follow-up requirements.","ALL","18 Years","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical study aims to evaluate the effectiveness of patient-specific 3D-printed titanium facial implants in the reconstruction and aesthetic correction of facial defects. The study will include patients presenting with congenital, traumatic, or post-surgical facial deformities requiring reconstructive intervention.\n\nEligible participants will undergo preoperative clinical assessment and radiological imaging to design customized implants using computer-aided design (CAD) and 3D printing technology. The implants will be fabricated from medical-grade titanium and surgically placed according to standardized maxillofacial reconstructive protocols.\n\nPostoperative follow-up will assess functional outcomes, implant stability, complication rates, and aesthetic improvement over a defined observation period. Outcome evaluation will include clinical examination and patient-reported satisfaction measures.\n\nThe objective of this study is to determine whether patient-specific 3D-printed titanium implants provide reliable functional restoration and improved aesthetic outcomes in facial reconstruction compared to conventional reconstructive techniques.",[28,29,30,31,32,33],"Hemifacial Microsomia","Mucormycosis","Oral Squamous Cell Carcinoma","Microgenia","Facial Asymmetry","Fibrous Dysplasia",[35],"3D-Printed Titanium Implant * Facial Reconstruction","RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-17","ACTUAL",{"date":42,"type":40},"2026-04-26",{"date":44,"type":22},"2026-11-01",{"name":46,"class":47},"Tishreen University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100470452","biomarkers-for-invasive-mucormycosis-100470452","NCT05406037","Biomarkers for Invasive Mucormycosis","Diagnostic Marker of Mucormycosis : Development and Evaluation of a Diagnostic Assay on a Cohort of Sera","BIM","Inclusion Criteria:\n\n* Men and women\n* Age : Children and adults from 3 to 64 years old (18 to 64 for controls)\n* In patients whose consent has been collected after information. In the case of children, information on the study will be given to the holders of parental authority and then to the child to obtain their consent.\n* Patient social insured\n* Specific medical conditions :\n\n  1. For the case group :\n\n     Any patient hospitalized in one of the departments of the University Hospital of Lille, in which the diagnosis of mucormycosis was conducted on the following criteria:\n     * Conventional mycology data and \u002F or\n     * Positivity of q-PRC and \u002F or\n     * Anatomopathologic diagnosis Associated with a compatible clinical situation\n  2. For the control group 1 Patient assessed for hematopoietic stem cell transplantation, considered at risk for IFI but for whom the pre-transplantation review will have excluded an ongoing infection\n  3. For control group 2 Any patient hospitalized in a department of Lille University Hospital, in which the diagnosis of disseminated candidiasis or invasive pulmonary aspergillosis has been made according to specific classifications (EORTC\u002FMSG criteria, AspICU criteria)\n\nExclusion Criteria:\n\n* Patients for whom the inclusion criteria are not met\n* Co-infection mucormycosis\u002Fother IFI",true,"3 Years","64 Years",{"count":61,"type":22},100,"OBSERVATIONAL","Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization. Prompt initiation of adequate antifungal therapy is critical for treating mucormycosis. Early diagnostic is therefore essential. The presence in the Mucorales' cell wall of uncommon monosaccharides open interesting perspectives for the development of specific diagnostic biomarkers.\n\nThis study evaluate a diagnostic test for mucormycosis in a cohort of patients with MM and in control groups (high-risk patients without MM and patients with another IFI).",[65,29],"Mucorales Infection",[29,67,68,69],"Invasive fungal infection","Cell wall oligo\u002Fpolysaccharides","Biomarkers","2026-05-20",{"date":72,"type":40},"2026-05-22",{"date":74,"type":40},"2023-11-29",{"date":76,"type":22},"2026-07",{"name":78,"class":47},"University Hospital, Lille",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":48},"100583578","mucormycosis-clinical-core-for-the-mucor-advance-p01-project-100583578","NCT06878144","Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project","MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project (Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk Stratification, Diagnosis and Management of the Disease)","Inclusion Criteria:\n\n* Patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection.\n* Patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care.\n\nExclusion Criteria:\n\n• Patients who are unwilling to undergo routine diagnostic procedures as part of their regular care.","100 Years",{"count":88,"type":22},300,"To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.",[29],"NOT_YET_RECRUITING","2025-09-05",{"date":94,"type":40},"2025-09-08",{"date":96,"type":22},"2025-09-30",{"date":98,"type":22},"2032-12-31",{"name":100,"class":47},"M.D. Anderson Cancer Center",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":62,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100599120","isavuconazole-in-critically-ill-patients-efficacy-and-safety-100599120","NCT07080359","Isavuconazole in Critically Ill Patients: Efficacy and Safety","Isavuconazole in Critically Ill Patients: A Study on Antifungal Efficacy and Safety","Inclusion Criteria:\n\n* Adult critically ill patients (≥18 years) admitted to ICU with suspected or confirmed invasive fungal infection (IFI)\n* IFI diagnosis per EORTC\u002FMSGERC 2019 criteria\n\nExclusion Criteria:\n\n* Drug allergy\n* Inherited short QT syndrome\n* Contraindications for nasogastric\u002Foral drug delivery\n* \\\u003C18 years old",{"count":109,"type":22},75,"3 Months","Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.\n\nThis study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:\n\n1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients;\n2. Clinical outcomes;\n3. Adverse effects.",[113,114,29],"Fungal Infection","Aspergillosis","2025-07-14",{"date":117,"type":40},"2025-07-23",{"date":119,"type":22},"2025-08-01",{"date":121,"type":22},"2030-12-31",{"name":123,"class":47},"Shanghai 10th People's Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":48},"100549965","study-on-theraputic-drug-monitoring-and-phamacokinetics-of-isavuconazole-in-children-100549965","NCT06440915","Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children","Inclusion Criteria:\n\n* Patients who intend to take isavuconazole for the treatment of invasive mycosis;\n* Aged 0-18 years, gender unlimited;\n* The subject and his\u002Fher guardian are willing to comply with the procedures and operations specified in the study protocol;\n* The guardian of the subject and the subject of independent informed age are willing and able to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* The subject is known to be allergic to any azole antifungal therapy or other ingredients contained in the study drug;\n* The researcher believes that the condition of the child may interfere with study participation or other inappropriate conditions.",{"count":131,"type":22},200,[25],"The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric patients. The main questions it aims to answer are:\n\nWhat is the plasma concentration after using isavuconazole in pediatric patients? What is the effective range of plasma concentration of isavuconazole in pediatric patients? What is the safe range of plasma concentration of isavuconazole in pediatric patients? Researchers will measure the plasma concentration of isavuconazole to see whether it is appropriate.\n\nParticipants will:\n\nTake drug isavuconazole as prescribed by the doctor;\n\n1mL of blood is drawn 30min before the next dose.",[135,29],"Aspergillosis Invasive","2024-12-09",{"date":138,"type":40},"2024-12-13",{"date":140,"type":40},"2024-06-06",{"date":142,"type":22},"2026-06-30",{"name":144,"class":47},"Shanghai Children's Medical Center"]